CorxelBio

Corxel Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardiometabolic and ophthalmic conditions. Headquartered in the United States and China, the company was founded in 2019 by RTW Investments and has since secured significant backing from global investors including Bayer and RA Capital. Corxel's pipeline is anchored by CX11, a potentially best-in-class oral small molecule GLP-1 receptor agonist for obesity and diabetes, and JX10, a novel treatment for acute ischemic stroke currently in global registrational trials. The company employs a strategic model of in-licensing high-potential assets and advancing them through global clinical development and regulatory approval. With a leadership team drawn from major multinational pharmaceutical companies, Corxel is positioned to address massive unmet needs in the global cardiometabolic market.